The startup develops genetically engineered pigs for use in regenerative medicine and xenotransplantation, providing a reliable model for drug efficacy and medical device performance testing. This approach addresses the critical shortage of organ donations by enabling the evaluation of potential therapeutic solutions in personalized medicine.
Funding
Funding not disclosed
Founders
Product
Problem
The severe shortage of human organ donors results in many patients with organ failure being unable to receive life-saving transplants. Current solutions, such as artificial dialysis, can be costly and reduce the patient's quality of life.
Solution
PorMedTec develops genetically engineered Designated Pathogen Free (DPF) pigs to address the critical shortage of organs for xenotransplantation and regenerative medicine. By leveraging advanced bioengineering technologies, including somatic cell cloning and gene editing, PorMedTec creates pigs with organs that are compatible for human transplantation. The company aims to provide a cost-effective and stable supply of transplantable organs, tissues, and cells to patients with organ failure, offering a potential solution to the global organ shortage.
Target Audience
The primary target audience includes medical institutions, transplant centers, and research organizations focused on regenerative medicine, xenotransplantation, and developing therapies for organ failure.
Features
- Utilizes somatic cell cloning to produce genetically modified pigs with improved traits for medical use.
- Employs a Uterectomy Isolated Rearing (U-iR) system to produce Designated Pathogen Free (DPF) pigs, meeting the hygienic standards for xenotransplantation.
- Applies gene editing to modify porcine somatic and embryonic cells to enhance compatibility with the human immune system.
- Offers technical consulting services for cryopreservation of biomaterials, including fetal anlagens, pancreatic islets, organoids, and artificial tissues.
- Provides made-to-order production of genetically engineered pigs tailored to specific research and therapeutic needs.
- Conducts research and development in islet xenotransplantation and transplantation therapy with humanized kidneys.